A cutting-edge machine-learning model has the pharmaceutical world buzzing with its potential to pinpoint harmful drug combos before they cause any real trouble. This leap in drug safety comes from researchers at MIT, Brigham and Women's Hospital, and Duke University who've developed a way to identify which cellular transporters various drugs use to pass through the gut, as reported by MIT News.
The resourcefulness of the model lies squarely in its ability to rapidly predict how certain drugs might clash in the body, a benefit not to be taken lightly, particularly when considering the stakes of prescribing ineffective or even dangerous medication combos. Giovanni Traverso, an associate professor at MIT and a gastroenterologist at Brigham and Women’s Hospital, stated, "This study is all about how we can model those interactions, which could help us make drugs safer and more efficacious, and predict potential toxicities that may have been difficult to predict until now."
It seems that a handful of drugs, like the antibiotic doxycycline and the blood thinner warfarin, could be more of frenemies than friends. Their interaction was among the nearly 2 million flagged by the model. What’s more, the trouble doesn't stop there; doxycycline might also tango poorly with heart failure drug digoxin, antiseizure medication levetiracetam, and immunosuppressant tacrolimus. Historically, the guessing game of drug interactions has put patients at unforeseen risk, but this tool promises to minimize the gamble on patients’ health.
To double-check their model like a good math student always should, the researchers turned to real-world data, confirming their suspicions that doxycycline can certainly cause levels of warfarin in the bloodstream to spike, and then drop after discontinuing the antibiotic. Despite such findings being no less than a revelation in the field of drug safety, the model has been keenly eyed for its potential to prevent drug interaction issues right from the development phase of new medications. Former MIT postdoc and now Vivtex co-founder, Thomas von Erlach, together with his colleagues, are looking to take this prevention strategy and run all the way to healthier future drug development.
This breakthrough is not only about preventing adverse effects; it's also about paving the way for drugs to be more effectively absorbed in the body. The approach developed by the researchers could allow drug developers to add excipients to new drugs, enhancing their interaction with transporters and thus their availability within the body. The big brains behind the research and this novel approach were funded by notables like the U.S. National Institutes of Health, MIT's Department of Mechanical Engineering, and Brigham and Women’s Hospital's Division of Gastroenterology. And believe it or not, this team included MIT Institute Professor Robert Langer and a whole roster of medical and engineering talent.
